Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.1% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes (TNDM) operates in the diabetes management solutions sector, amid promising growth in the medical devices and healthcare technology market.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 5.1% on Dec 17, 2024 14:40

• Today's positive performance of TNDM stock is linked to the recent announcement of the successful integration of their t:slim X2 insulin pump with Dexcom G7 CGM in Canada.
• This debut in the Canadian market presents a new opportunity for Tandem Diabetes and enriches their product portfolio, potentially boosting investor confidence in the company's future growth.
• The partnership with Dexcom to merge their technologies showcases Tandem Diabetes' dedication to innovation and competitiveness in the diabetes management industry, a move that has resonated positively with investors.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada

Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.

https://www.zacks.com/stock/news/2383212/tndm-stock-to-gain-from-tslim-x2-with-dexcom-g7-launch-in-canada

Trending Today

Aave ($AAVE) Crypto Forecast: Up 11.2% Today

Xerox Corporation ($XRX) Stock Forecast: Down 4.2% Today

Cassava Sciences, Inc. ($SAVA) Stock Forecast: Up 6.0% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 5.1% Today

Sui ($SUI) Crypto Forecast: Down 5.1% Today

dogwifhat ($WIF) Crypto Forecast: Down 5.5% Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Up 5.2% Today

Horizen ($ZEN) Crypto Forecast: Up 7.6% Today

Algorand ($ALGO) Crypto Forecast: Up 10.7% Today

Injective ($INJ) Crypto Forecast: Up 5.7% Today

Tandem Diabetes Care, Inc. Price History

26.08.2024 - TNDM Stock was down 5.9%

• The announcement regarding the compatibility of Tandem Diabetes' t:slim X2 insulin pump with Lilly's Lyumjev in the EU has the potential to boost market share and revenue for TNDM.
• Despite this development, the stock witnessed a downward trend today, possibly due to investors selling shares to lock in profits from earlier purchases made in anticipation of this announcement.
• It's also conceivable that general market conditions or factors specific to the sector played a role in driving the bearish movement of TNDM stock today, potentially overshadowing the positive news related to the new product offering in the EU.

20.07.2024 - TNDM Stock was down 5.2%

• The recent launch of the updated iOS t:connect mobile app to address issues from a previous nationwide recall has sparked investor concerns regarding the company's product quality and potential sales impact.
• Comparisons made between Tandem Diabetes Care and other diabetes-related stocks may have exposed vulnerabilities or obstacles the company is currently encountering, thereby resulting in a pessimistic response from traders.
• The competitive environment within the diabetes care industry, along with the escalating global prevalence of diabetes, likely contributed to the market's negative stance on TNDM's stock performance today.

08.10.2024 - TNDM Stock was down 5.9%

• Tandem Diabetes (TNDM) is a company focusing on diabetes management products. The overall market sentiment for TNDM was bearish today.
• TNDM reported strong Q3 earnings, surpassing expectations and increasing sales projections for 2024.
• Despite the positive earnings report, the stock fell in aftermarket trading.
• The market may have reacted negatively due to profit-taking by investors after a period of strong performance, or there could be concerns about future growth prospects despite the upbeat guidance.

10.11.2024 - TNDM Stock was up 5.4%

• The strong bullish movement in TNDM could be attributed to positive market sentiment following potential clues in earnings estimates.
• Investors might be optimistic about TNDM's ability to rebound from the previous 9.2% decline since the last earnings report.
• The market movement suggests that there is renewed confidence in TNDM's future performance, possibly driven by promising developments or growth prospects in the diabetes management sector.

10.09.2024 - TNDM Stock was down 7.3%

• Analyst coverage by David Roman from Goldman Sachs with a bullish note on MINISO Group Holding (MNSO) may have diverted investor attention from Tandem Diabetes Care, Inc., impacting TNDM stock negatively.
• The optimistic outlook on MNSO might have enticed investors seeking new opportunities, leading to a shift in focus and funds away from TNDM.
• This change in investor sentiment, influenced by the analyst coverage on MNSO, could have caused a lack of buying support for TNDM, contributing to its bearish performance today.

23.09.2024 - TNDM Stock was down 5.0%

• Recently, Tandem Diabetes Care (TNDM) has faced a downward trend with considerable selling pressure, resulting in a bearish movement in its stock price.
• The stock is currently in oversold territory from a technical standpoint, indicating a potential halt in heavy selling pressure, possibly signaling a reversal of trend in the near term.
• The consensus among Wall Street analysts in upwardly revising earnings estimates suggests a potential turnaround for Tandem Diabetes Care, positioning it as a stock worth monitoring for potential recovery.

05.10.2024 - TNDM Stock was up 5.3%

• Analysts predicted a decline in TNDM's earnings, but the market showed a bullish trend, suggesting diverging investor expectations.
• The anticipation of an upcoming earnings announcement might have sparked greater investor interest and buying, resulting in a surge in the stock price.
• Investors seem optimistic about TNDM's growth prospects and potential for innovation in the diabetes management sector, driving the bullish trend.
• Recent product developments or strategic partnerships by TNDM could have boosted investor confidence, fueling the strong bullish movement in the stock price.

17.11.2024 - TNDM Stock was up 5.1%

• Today's positive performance of TNDM stock is linked to the recent announcement of the successful integration of their t:slim X2 insulin pump with Dexcom G7 CGM in Canada.
• This debut in the Canadian market presents a new opportunity for Tandem Diabetes and enriches their product portfolio, potentially boosting investor confidence in the company's future growth.
• The partnership with Dexcom to merge their technologies showcases Tandem Diabetes' dedication to innovation and competitiveness in the diabetes management industry, a move that has resonated positively with investors.

26.06.2024 - TNDM Stock was down 8.7%

• TNDM saw a notable decline, likely influenced by DexCom's unfavorable revenue performance and less optimistic guidance.
• The downbeat updates from DexCom may have shaken investor belief in the diabetes care field, triggering a wave of selling in companies like TNDM.
• Investors could be feeling uncertain about the diabetes care industry's prospects, prompting a reassessment of their investments in TNDM and comparable firms.

06.07.2024 - TNDM Stock was up 7.7%

• Tandem Diabetes Care Inc. (TNDM) witnessed a notable surge in its stock price today, attributed to the positive second-quarter financial results.
• The company exceeded analyst expectations, with earnings per share recorded at -48 cents and revenue reaching $221.91 million.
• The favorable financial performance showcased in the recent report likely fueled the increase in the company's stock value, underscoring its competencies in the competitive healthcare sector.
• Given the rising demand for telemedicine solutions and Tandem Diabetes Care Inc.'s emphasis on diabetes management offerings, the company appears to be strongly positioned for future expansion and achievements.

13.07.2024 - TNDM Stock was up 5.7%

• Tandem Diabetes Care (TNDM) saw a significant uptrend likely linked to recent updates about the March 2024 nationwide recall of its t:connect mobile app for iOS devices.
• The company's communication addressing the issue of fast depletion of the insulin pump battery and the planned release of a new app version for enhanced safety likely boosted confidence among investors and consumers.
• Tandem Diabetes Care's proactive handling of the recall and emphasis on user safety may have influenced the favorable market reaction, demonstrating its dedication to quality and customer satisfaction.

02.07.2024 - TNDM Stock was up 16.1%

• Tandem Diabetes Care's stock surged by 16% subsequent to the announcement of their second-quarter earnings, which surpassed projections.
• The company outperformed analyst forecasts for both earnings per share and revenue, indicating robust financial performance and potentially fostering investor confidence.
• The increase in Tandem Diabetes Care's price target and favorable rating following their Q2 results further bolstered the optimistic sentiment surrounding the stock.
• The favorable market outlook for Tandem Diabetes Care might be attributed to the company's ability to surpass expectations and display growth prospects in the diabetes management sector.